“Huge News for CVS Stock Investors”
AI summary · The reported plan to spin off CVS's retail pharmacy business, which faces fewer store visits and rising wages, is a positive development that makes the speaker more optimistic about CVS long term; he reaffirms his buy rating with low confidence and conviction. At $91.41 CVS trades below his fair value estimate of over $120, and its forward P/E of 10.72 is below Wall Street's ~12% EPS growth forecast, though over $74 billion in long-term debt is a key concern.
We have huge news for CVS stock investors, as Bloomberg reports that the company is discussing plans to spin off its retail pharmacy business. This could be a huge undertaking, given that CVS Health is one of the largest companies in the world, both in terms of its revenue over the past twelve months and the number of its existing locations.